These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Verapamil and 24-hour ambulatory blood pressure monitoring in essential hypertension. Zachariah PK; Sheps SG; Schirger A; Spiekerman RE; O'Brien PC; Simpson KK Am J Cardiol; 1986 Feb; 57(7):74D-79D. PubMed ID: 3953429 [TBL] [Abstract][Full Text] [Related]
4. Trough-to-peak ratio and circadian blood pressure profile after treatment with once-daily extended-release diltiazem, 240 mg, in patients with mild-to-moderate essential hypertension. Coca A; Sobrino J; Soler J; Módol J; Palos MA; Mínguez A; Esqúe J; Plana J; Cases M; Closas J; de la Sierra A J Cardiovasc Pharmacol; 1997 Mar; 29(3):316-22. PubMed ID: 9125668 [TBL] [Abstract][Full Text] [Related]
5. Assessment of 'once daily' verapamil for the treatment of hypertension using ambulatory, intra-arterial blood pressure recording. Caruana M; Heber M; Brigden G; Raftery EB Eur J Clin Pharmacol; 1987; 32(6):549-53. PubMed ID: 3653223 [TBL] [Abstract][Full Text] [Related]
6. Verapamil 240 SR versus verapamil 120 SR in arterial hypertension. A randomized double-blind, placebo-controlled study with 24-hour ambulatory blood pressure monitoring. Corea L; Bentivoglio M; Berioli S; Bianchini C; Savino K; Sardina M Cardiovasc Drugs Ther; 1990 Dec; 4(6):1501-7. PubMed ID: 2081142 [TBL] [Abstract][Full Text] [Related]
7. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Bakris G; Sica D; Ram V; Fagan T; Vaitkus PT; Anders RJ Am J Hypertens; 2002 Jan; 15(1 Pt 1):53-7. PubMed ID: 11824861 [TBL] [Abstract][Full Text] [Related]
8. Treatment of mild hypertension with low once-daily doses of a sustained-release capsule formulation of verapamil. Davis PJ; Fagan TC; Topmiller MJ; Levine JH; Ferdinand KC J Clin Pharmacol; 1995 Jan; 35(1):52-8. PubMed ID: 7751413 [TBL] [Abstract][Full Text] [Related]
9. Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. White WB; Sica DA; Calhoun D; Mansoor GA; Anders RJ Am Heart J; 2002 Oct; 144(4):657-65. PubMed ID: 12360162 [TBL] [Abstract][Full Text] [Related]
10. Twenty-four-hour blood pressure monitoring after a single dose of sustained-release verapamil. Cardillo C; Musumeci V; Mores N; Baroni S; Cremona G; Tutinelli F; Folli G Cardiovasc Drugs Ther; 1988 Nov; 2(4):533-7. PubMed ID: 3154631 [TBL] [Abstract][Full Text] [Related]
11. [Plasma levels and noninvasive hemodynamic profile of slow release verapamil (240 mg). A multicenter study]. Vulpis V; Seccia TM; Ricci S; Pirrelli A Riv Eur Sci Med Farmacol; 1993; 15(5-6):227-35. PubMed ID: 7761676 [TBL] [Abstract][Full Text] [Related]
12. Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapy. White WB; Johnson MF; Black HR; Elliott WJ; Sica DA Am J Hypertens; 2001 Dec; 14(12):1239-47. PubMed ID: 11775133 [TBL] [Abstract][Full Text] [Related]
13. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension. Muijsers RB; Curran MP; Perry CM Drugs; 2002; 62(17):2539-67. PubMed ID: 12421112 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study. Speders S; Sosna J; Schumacher A; Pfennigsdorf G J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S47-9. PubMed ID: 2475686 [TBL] [Abstract][Full Text] [Related]
15. Treatment of mild to moderate hypertension with verapamil slow-release in outpatients. Collaborative Group of the Spanish League for the Fight Against Hypertension. Gómez Pajuelo C; Pérez Naranjo J; Ruiz Martínez I J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S50-2. PubMed ID: 2475687 [TBL] [Abstract][Full Text] [Related]
16. [A Brazilian multicenter study to evaluate the clinical effectiveness and tolerance of isradipine SRO using ambulatory monitoring of arterial pressure in the treatment of mild and moderate arterial hypertension]. Magliano MF; Amodeo C; Mion Júnior D; Francischetti E; Lima Júnior E; Nobre F; Chaves H; Ribeiro JM; Spritzer N; Jardim PC Arq Bras Cardiol; 1993 Nov; 61(5):311-8. PubMed ID: 8147731 [TBL] [Abstract][Full Text] [Related]
17. Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning. Neutel JM; Alderman M; Anders RJ; Weber MA Am Heart J; 1996 Dec; 132(6):1202-6. PubMed ID: 8969572 [TBL] [Abstract][Full Text] [Related]
18. The effects of slow-release verapamil on blood pressure and cardiovascular system in essential hypertension. Meric M; Adalet K; Erzengin F; Korkut F; Okur O; Büyüköztürk K J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S42-4. PubMed ID: 2475684 [TBL] [Abstract][Full Text] [Related]
19. The role of a slow channel inhibitor, verapamil, in the management of hypertension. Gould BA; Mann S; Kieso H; Subramanian VB; Raftery EB Acta Med Scand Suppl; 1984; 681():117-23. PubMed ID: 6587750 [TBL] [Abstract][Full Text] [Related]
20. [Evaluation of the antihypertensive efficacy and safety of using sustained release verapamil in elderly subjects using ambulatory blood pressure monitoring]. Jasiński T; Janicki K; Klima M; Pieniazek W; Bednarz S Przegl Lek; 1996; 53(2):73-7. PubMed ID: 8754325 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]